261 related articles for article (PubMed ID: 29920744)
1. Linear bullous lichen planus associated with nivolumab.
Biolo G; Caroppo F; Salmaso R; Alaibac M
Clin Exp Dermatol; 2019 Jan; 44(1):67-68. PubMed ID: 29920744
[No Abstract] [Full Text] [Related]
2. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
[TBL] [Abstract][Full Text] [Related]
3. Multiple erosive lichen planus preceded by solitary lichen planus after combination therapy with nivolumab and radiation.
Komori T; Honda T; Irie H; Otsuka A; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e382-e384. PubMed ID: 28295693
[No Abstract] [Full Text] [Related]
4. Nivolumab-induced lichen planus pemphigoides.
Strickley JD; Vence LM; Burton SK; Callen JP
Cutis; 2019 Apr; 103(4):224-226. PubMed ID: 31116807
[TBL] [Abstract][Full Text] [Related]
5. Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy.
Miyagawa F; Nakajima A; Ohyama SI; Aoki Y; Nishikawa M; Nakamura Y; Hashimoto T; Asada H
Acta Derm Venereol; 2019 Jun; 99(7):687-688. PubMed ID: 30938822
[No Abstract] [Full Text] [Related]
6. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.
Sato Y; Fujimura T; Mizuashi M; Aiba S
J Dermatol; 2019 Oct; 46(10):e374-e375. PubMed ID: 31062404
[No Abstract] [Full Text] [Related]
7. Disseminated erythema with intense and selective inflammation of sweat gland and lichenoid drug eruption during nivolumab therapy.
Matsumoto Y; Kadono T; Matsuoka M; Kawakami T; Furuya N; Doi M; Hoshikawa M; Soma Y
J Dermatol; 2018 Feb; 45(2):e33-e34. PubMed ID: 28984022
[No Abstract] [Full Text] [Related]
8. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.
Kwon CW; Land AS; Smoller BR; Scott G; Beck LA; Mercurio MG
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e349-e350. PubMed ID: 28129461
[No Abstract] [Full Text] [Related]
9. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
[TBL] [Abstract][Full Text] [Related]
10. Bullous lichen planus caused by labetalol.
Gange RW; Jones EW
Br Med J; 1978 Apr; 1(6116):816-7. PubMed ID: 346143
[No Abstract] [Full Text] [Related]
11. Umbilical lichen planus induced by nivolumab.
Martos-Cabrera L; Lladó I; Fernández-Rico P; Butrón-Bris B; Rodríguez-Jiménez P
An Bras Dermatol; 2023; 98(5):712-714. PubMed ID: 37164791
[No Abstract] [Full Text] [Related]
12. Drug-induced bullous lichen planus in a patient with diabetes mellitus and liver disease.
Hsiao L; Yoshinaga A; Ono T
J Am Acad Dermatol; 1986 Jul; 15(1):103-5. PubMed ID: 3522669
[No Abstract] [Full Text] [Related]
13. Nivolumab-induced lichen planus.
Yilmaz M; Mese SG; Celik U
J Oncol Pharm Pract; 2020 Apr; 26(3):758-760. PubMed ID: 31382865
[TBL] [Abstract][Full Text] [Related]
14. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
Karakas Y; Yuce D; Kılıckap S
Oncol Res Treat; 2017; 40(10):621-622. PubMed ID: 28950270
[No Abstract] [Full Text] [Related]
15. A Cautionary Note: "Real-World" Toxicity of Checkpoint Inhibitors.
Markman M
Oncology; 2018; 94(5):257-258. PubMed ID: 29444519
[No Abstract] [Full Text] [Related]
16. Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after programmed cell death 1 inhibition with nivolumab.
Feldstein SI; Patel F; Larsen L; Kim E; Hwang S; Fung MA
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e58-e59. PubMed ID: 28776778
[No Abstract] [Full Text] [Related]
17. New onset of psoriasis during nivolumab treatment for lung cancer.
Chujo S; Asahina A; Itoh Y; Kobayashi K; Sueki H; Ishiji T; Umezawa Y; Nakagawa H
J Dermatol; 2018 Mar; 45(3):e55-e56. PubMed ID: 29205470
[No Abstract] [Full Text] [Related]
18. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
19. Naproxen-induced lichen planus bullosus.
Ozkan S; Izler F; Fetil E; Dorak F; Güneş T
Acta Derm Venereol; 1999 Jul; 79(4):329-30. PubMed ID: 10430000
[No Abstract] [Full Text] [Related]
20. Nivolumab-related lichen planus of the lip in a patient with head and neck cancer.
Economopoulou P; Nicolatou-Galitis O; Kotsantis I; Psyrri A
Oral Oncol; 2020 May; 104():104623. PubMed ID: 32144002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]